Know Cancer

or
forgot password

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer


Phase 2
N/A
N/A
Not Enrolling
Both
Head and Neck Cancer

Thank you

Trial Information

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer


Inclusion Criteria:



- Subjects with advanced head and neck cancer who have completed the previous late
phase 2 study (CA139-388) and should have continued therapy with aclitaxel as the
discretion of the investigator

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Adverse event

Outcome Time Frame:

Throughout the study

Safety Issue:

Yes

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

Japan: Pharmaceuticals and Medical Devices Agency

Study ID:

CA139-539

NCT ID:

NCT00971867

Start Date:

August 2006

Completion Date:

November 2008

Related Keywords:

  • Head and Neck Cancer
  • Head and Neck Neoplasms

Name

Location